Longevity & AgingGLP-1 drugs deliver big benefits but demand smarter safety monitoring and patient selection
GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide are widely used for type 2 diabetes and obesity, and their benefits are well established. This narrative review examines their safety and tolerability. Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are the most common and usually appear during dose escalation, then fade. Gallbladder disease, gastroparesis, and bowel obstruction need caution in susceptible people. Injection-site reactions and worsening of existing diabetic retinopathy are also relevant. Rare signals include optic neuropathy, pancreatitis, and medullary thyroid carcinoma, mostly from pharmacovigilance and case reports. Large studies suggest no significant increase in acute kidney injury, and no confirmed rise in suicidality, though monitoring continues. Data in pregnancy, lactation, children, and advanced kidney or liver disease are limited. The authors stress individualized care and ongoing surveillance.